Joe Biden will be inaugurated as the 46th President on Wednesday and investors are looking for investment opportunities to prepare for the Biden Presidency. Cannabis is one of the sectors that could benefit from Biden's policy platform.
Could that platform include federally decriminalizing cannabis and legalizing it for recreational use as states like Colorado, Massachusetts and California have done already?
If you're looking for the best stocks to invest in in the cannabis sector, TheStreet's Debra Borchardt recently shared her top stock picks in the cannabis sector for 2021.
Here is a list of the cannabis stocks to watch and their performance from this past week by the percentage change at the close of trading on Jan 8.
Aurora Cannabis Inc | Increased +13.41% | Price $11.84
TheStreet Quant Ratings rates Aurora Cannabis Inc. as a Sell with a rating score of D-.
Aphria Inc. | Increased +45.09% | Price $12.42
TheStreet Quant Ratings rates Aphria as a Sell with a rating score of D.
Tilray Inc | Increased +55.31% | Price $19.15
TheStreet Quant Ratings rates Tilray as a Sell with a rating score of D-.
Canopy Growth Corp | Increased +6.45% | Price $33.50
Canopy Growth (CGC) - Get Canopy Growth Corporation Report filed an early warning report this past week in connection with the acquisition of an option to purchase 1,072,450 common shares of TerrAscend Corp.
Real Money writer Bruce Kamich looked at the charts for Canopy Growth to see how investors should trade.
TheStreet Quant Ratings rates Canopy Growth Corp as a Hold with a rating score of C.
GW Pharma | Increased +5.87% | Price $135.73
TheStreet Quant Ratings rates GW Pharma as a Sell with a rating score of D+.
Cronos Group CRON | Increased +11.33% | Price $10.91
TheStreet Quant Ratings rates Cronos Group as a Hold with a rating score of C.
NOTE: Recently, Quantitative Analysis by TheStreet Quant Ratings objectively rated these stocks according to its risk-adjusted total return prospect over a 12-month investment horizon. Not based on the news on any given day, the rating may differ from Jim Cramer's view or that of this articles' author.